Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Hein

Showing results (91-100 of 169) with videos related to

Pageof 17
Sort By:
Plos One|June 16, 2011
Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association ConsortiumGalina Lurie, Lynne R Wilkens, Pamela J Thompson, et al.
International Journal of Cancer|July 11, 2025
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trialMilena Beierlein, Lothar Häberle, Naiba Nabieva, et al.
International Journal of Cancer|March 23, 2019
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patientsNaiba Nabieva, Lothar Häberle, Sara Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|May 1, 2024
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace StudyCarolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 11, 2012
Polymorphisms in inflammation pathway genes and endometrial cancer riskRyan J Delahanty, Yong-Bing Xiang, Amanda Spurdle, et al.
Breast Care (Basel, Switzerland)|December 7, 2016
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyPaul Gaß, Peter A Fasching, Tanja Fehm, et al.
Integrative Cancer Therapies|September 16, 2016
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyCarolin C Hack, Peter A Fasching, Tanja Fehm, et al.
Breast Cancer Research and Treatment|April 2, 2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trialManuel Hörner, Lara M Tretschock, Nelson John, et al.
Breast Cancer Research and Treatment|January 4, 2019
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancerMarius Wunderle, Jutta Pretscher, Sara Y Brucker, et al.
BMC Cancer|June 23, 2019
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM studyMarkus Wallwiener, Naiba Nabieva, Manuel Feisst, et al.
Pageof 17

Showing results (91-100 of 169) with videos related to

Sort By:
Pageof 17
Plos One|June 16, 2011
Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association ConsortiumGalina Lurie, Lynne R Wilkens, Pamela J Thompson, et al.
International Journal of Cancer|July 11, 2025
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trialMilena Beierlein, Lothar Häberle, Naiba Nabieva, et al.
International Journal of Cancer|March 23, 2019
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patientsNaiba Nabieva, Lothar Häberle, Sara Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|May 1, 2024
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace StudyCarolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 11, 2012
Polymorphisms in inflammation pathway genes and endometrial cancer riskRyan J Delahanty, Yong-Bing Xiang, Amanda Spurdle, et al.
Breast Care (Basel, Switzerland)|December 7, 2016
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyPaul Gaß, Peter A Fasching, Tanja Fehm, et al.
Integrative Cancer Therapies|September 16, 2016
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyCarolin C Hack, Peter A Fasching, Tanja Fehm, et al.
Breast Cancer Research and Treatment|April 2, 2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trialManuel Hörner, Lara M Tretschock, Nelson John, et al.
Breast Cancer Research and Treatment|January 4, 2019
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancerMarius Wunderle, Jutta Pretscher, Sara Y Brucker, et al.
BMC Cancer|June 23, 2019
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM studyMarkus Wallwiener, Naiba Nabieva, Manuel Feisst, et al.
Pageof 17